Crossject Société Anonyme (ALCJ.PA)

EUR 2.0

(1.01%)

EBITDA Summary of Crossject Société Anonyme

  • Crossject Société Anonyme's latest annual EBITDA in 2023 was -7.29 Million EUR , down -24.32% from previous year.
  • Crossject Société Anonyme's latest quarterly EBITDA in 2024 Q2 was -6.19 Million EUR , down 0.0% from previous quarter.
  • Crossject Société Anonyme reported an annual EBITDA of -8.02 Million EUR in 2022, down -5.52% from previous year.
  • Crossject Société Anonyme reported an annual EBITDA of -7.33 Million EUR in 2021, down -8.71% from previous year.
  • Crossject Société Anonyme reported a quarterly EBITDA of -4.9 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Crossject Société Anonyme reported a quarterly EBITDA of N/A for 2023 FY, down -24.32% from previous quarter.

Annual EBITDA Chart of Crossject Société Anonyme (2023 - 2010)

Historical Annual EBITDA of Crossject Société Anonyme (2023 - 2010)

Year EBITDA EBITDA Growth
2023 -7.29 Million EUR -24.32%
2022 -8.02 Million EUR -5.52%
2021 -7.33 Million EUR -8.71%
2020 -7.13 Million EUR -26.78%
2019 -4.76 Million EUR 39.45%
2018 -9.04 Million EUR -34.6%
2017 -6.36 Million EUR -13.13%
2016 -5.93 Million EUR -32.71%
2015 -5.51 Million EUR -10.08%
2014 -4.22 Million EUR -110.79%
2013 -1.54 Million EUR -113.91%
2012 -681.01 Thousand EUR 11.02%
2011 -1.01 Million EUR 72.38%
2010 -3.66 Million EUR 0.0%

Peer EBITDA Comparison of Crossject Société Anonyme

Name EBITDA EBITDA Difference
Safe Orthopaedics SA -5.62 Million EUR -29.73%
Spineway SA -4.79 Million EUR -52.286%
Amplitude Surgical SA 24.72 Million EUR 129.505%
Sartorius Stedim Biotech S.A. 777.2 Million EUR 100.939%
EssilorLuxottica Société anonyme 6.18 Billion EUR 100.118%
bonyf N.V. -39.89 Thousand EUR -18188.423%